Allogene Therapeutics Inc... (ALLO)
Allogene Therapeutics Statistics
Share Statistics
Allogene Therapeutics has 217.26M shares outstanding. The number of shares has increased by 4.06% in one year.
| Shares Outstanding | 217.26M |
| Shares Change (YoY) | 4.06% |
| Shares Change (QoQ) | 3.62% |
| Owned by Institutions (%) | 90.07% |
| Shares Floating | 139.53M |
| Failed to Deliver (FTD) Shares | 35.51K |
| FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 32.35M, so 15.43% of the outstanding shares have been sold short.
| Short Interest | 32.35M |
| Short % of Shares Out | 15.43% |
| Short % of Float | 22.75% |
| Short Ratio (days to cover) | 10.45 |
Valuation Ratios
The PE ratio is -1.61 and the forward PE ratio is -1.39. Allogene Therapeutics's PEG ratio is 0.04.
| PE Ratio | -1.61 |
| Forward PE | -1.39 |
| PS Ratio | 18861.32 |
| Forward PS | 0.7 |
| PB Ratio | 0.98 |
| P/FCF Ratio | -2.06 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Allogene Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.54, with a Debt / Equity ratio of 0.2.
| Current Ratio | 8.54 |
| Quick Ratio | 8.54 |
| Debt / Equity | 0.2 |
| Debt / EBITDA | -0.34 |
| Debt / FCF | -0.41 |
| Interest Coverage | -1509.39 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $97.35 |
| Profits Per Employee | $-1.14M |
| Employee Count | 226 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 443K |
| Effective Tax Rate | -0.17% |
Stock Price Statistics
The stock price has increased by -65.11% in the last 52 weeks. The beta is 0.99, so Allogene Therapeutics's price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | -65.11% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 2.32 |
| Relative Strength Index (RSI) | 38.83 |
| Average Volume (20 Days) | 5.49M |
Income Statement
In the last 12 months, Allogene Therapeutics had revenue of 22K and earned -257.59M in profits. Earnings per share was -1.32.
| Revenue | 22K |
| Gross Profit | 22K |
| Operating Income | -273.2M |
| Net Income | -257.59M |
| EBITDA | -243.33M |
| EBIT | -256.97M |
| Earnings Per Share (EPS) | -1.32 |
Balance Sheet
The company has 75.22M in cash and 83.25M in debt, giving a net cash position of -8.03M.
| Cash & Cash Equivalents | 75.22M |
| Total Debt | 83.25M |
| Net Cash | -8.03M |
| Retained Earnings | -1.82B |
| Total Assets | 548.71M |
| Working Capital | 267.86M |
Cash Flow
In the last 12 months, operating cash flow was -200.3M and capital expenditures -694K, giving a free cash flow of -200.99M.
| Operating Cash Flow | -200.3M |
| Capital Expenditures | -694K |
| Free Cash Flow | -200.99M |
| FCF Per Share | -1.03 |
Margins
Gross margin is 100%, with operating and profit margins of -1241813.64% and -1170863.64%.
| Gross Margin | 100% |
| Operating Margin | -1241813.64% |
| Pretax Margin | -1168850% |
| Profit Margin | -1170863.64% |
| EBITDA Margin | -1106031.82% |
| EBIT Margin | -1241813.64% |
| FCF Margin | -913609.09% |
Dividends & Yields
ALLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ALLO is $9, which is 533.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 533.8% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -4.23 |
| Piotroski F-Score | 2 |